AnderCorp Academy
Back to Market Scenarios

Johnson & Johnson Tylenol Cyanide Tampering Crisis

Sep 30, 1982 → Feb 17, 1983 JNJ — Johnson & Johnson intermediate

Market Context & Analysis

Starting Price: $46.00

Seven people die from cyanide-laced Tylenol capsules in Chicago. Product tampering, not manufacturing defect. J&J immediately recalls 31 million bottles worth $100 million. This becomes textbook crisis management case. Company prioritizes safety over profits, rebuilding trust.

Early 1980s recession recovering. Consumer products sector stable. Healthcare stocks generally defensive.

Incident leads to federal anti-tampering legislation. FBI investigation. Product safety becomes national issue.

Tylenol is J&J's bestselling product. Company acts decisively—recall and transparency. Introduces tamper-resistant packaging. CEO James Burke's leadership praised. Market share recovered within year.

Initial panic about product liability. Then recognition of exemplary crisis management. Diversified company cushions Tylenol impact. Trust in J&J brand strengthened long-term.

  • Seven deaths from product tampering
  • Immediate recall of all Tylenol—$100M cost
  • Crisis management textbook response
  • Tamper-resistant packaging innovation
  • Diversified product portfolio cushions impact
  • FDA and FBI involved in investigation
  • Long-term brand trust actually strengthened

Make Your Prediction

Price Direction
Expected Magnitude
Confidence Level

1 = Low confidence, 5 = High confidence

Your Reasoning